Correction to: Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment‑Refractory Nontuberculous Mycobacterial Lung Disease (European Journal of Drug Metabolism and Pharmacokinetics, (2021), 46, 2, (277-287), 10.1007/s13318-020-00669-7)

Christopher M. Rubino, Nikolas J. Onufrak, Jakko van Ingen, David E. Griffith, Sujata M. Bhavnani, Dayton W. Yuen, Kevin C. Mange, Kevin L. Winthrop

Research output: Contribution to journalComment/debatepeer-review

Abstract

A correction to this paper has been published: https://doi.org/10.1007/s13318-021-00687-z

Original languageEnglish (US)
Pages (from-to)573-574
Number of pages2
JournalEuropean Journal of Drug Metabolism and Pharmacokinetics
Volume46
Issue number4
DOIs
StatePublished - Jul 2021

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Correction to: Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment‑Refractory Nontuberculous Mycobacterial Lung Disease (European Journal of Drug Metabolism and Pharmacokinetics, (2021), 46, 2, (277-287), 10.1007/s13318-020-00669-7)'. Together they form a unique fingerprint.

Cite this